The U.S. DNA nanotechnology market size is calculated at USD 2.01 billion in 2025 and is forecasted to reach around USD 15.32 billion by 2034, accelerating at a CAGR of 25.26% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. DNA Nanotechnology Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. DNA Nanotechnology Market, by Type
8.1.1 Dynamic DNA Nanotechnology
8.1.1.1. Market Revenue and Forecast
8.1.2. Structural DNA Nanotechnology
8.1.2.1. Market Revenue and Forecast
9.1. U.S. DNA Nanotechnology Market, by Application
9.1.1. Smart Pills
9.1.1.1. Market Revenue and Forecast
9.1.2. Nanolithography
9.1.2.1. Market Revenue and Forecast
9.1.3. Targeted Drug Delivery
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. U.S. DNA Nanotechnology Market, by End-user
10.1.1. Academic & Research Institutions
10.1.1.1. Market Revenue and Forecast
10.1.2. Biotechnology and Pharmaceuticals
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by January
11.1.2. Market Revenue and Forecast, by February
11.1.3. Market Revenue and Forecast, by March
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by January
11.1.4.2. Market Revenue and Forecast, by February
11.1.4.3. Market Revenue and Forecast, by March
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by January
11.1.5.2. Market Revenue and Forecast, by February
11.1.5.3. Market Revenue and Forecast, by March
11.2. Europe
11.2.1. Market Revenue and Forecast, by January
11.2.2. Market Revenue and Forecast, by February
11.2.3. Market Revenue and Forecast, by March
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by January
11.2.4.2. Market Revenue and Forecast, by February
11.2.4.3. Market Revenue and Forecast, by March
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by January
11.2.5.2. Market Revenue and Forecast, by February
11.2.5.3. Market Revenue and Forecast, by March
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by January
11.2.6.2. Market Revenue and Forecast, by February
11.2.6.3. Market Revenue and Forecast, by March
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by January
11.2.7.2. Market Revenue and Forecast, by February
11.2.7.3. Market Revenue and Forecast, by March
11.3. APAC
11.3.1. Market Revenue and Forecast, by January
11.3.2. Market Revenue and Forecast, by February
11.3.3. Market Revenue and Forecast, by March
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by January
11.3.4.2. Market Revenue and Forecast, by February
11.3.4.3. Market Revenue and Forecast, by March
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by January
11.3.5.2. Market Revenue and Forecast, by February
11.3.5.3. Market Revenue and Forecast, by March
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by January
11.3.6.2. Market Revenue and Forecast, by February
11.3.6.3. Market Revenue and Forecast, by March
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by January
11.3.7.2. Market Revenue and Forecast, by February
11.3.7.3. Market Revenue and Forecast, by March
11.4. MEA
11.4.1. Market Revenue and Forecast, by January
11.4.2. Market Revenue and Forecast, by February
11.4.3. Market Revenue and Forecast, by March
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by January
11.4.4.2. Market Revenue and Forecast, by February
11.4.4.3. Market Revenue and Forecast, by March
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by January
11.4.5.2. Market Revenue and Forecast, by February
11.4.5.3. Market Revenue and Forecast, by March
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by January
11.4.6.2. Market Revenue and Forecast, by February
11.4.6.3. Market Revenue and Forecast, by March
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by January
11.4.7.2. Market Revenue and Forecast, by February
11.4.7.3. Market Revenue and Forecast, by March
11.5. Latin America
11.5.1. Market Revenue and Forecast, by January
11.5.2. Market Revenue and Forecast, by February
11.5.3. Market Revenue and Forecast, by March
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by January
11.5.4.2. Market Revenue and Forecast, by February
11.5.4.3. Market Revenue and Forecast, by March
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by January
11.5.5.2. Market Revenue and Forecast, by February
11.5.5.3. Market Revenue and Forecast, by March
12.1. Esya Labs
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. FOx BIOSYSTEMS
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Genisphere LLC
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. INOVIO Pharmaceuticals
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Nanovery
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Nanowerk
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Nomic
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Parabon NanoLabs, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Torus Biosystems
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample